N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing a novel delivery system for vaccines and cancer treatments, is pleased to announce the filing of its Patent Cooperation Treaty patent application for its novel delivery system, Nuvec®.
Nuvec® is licensed by the Company from the University of Queensland under their silica nanoparticle patent application, which is currently under prosecution before various national patent offices. The patent application that was filed by the Company is based on improvements made to the manufacturing process, as the Company has scaled up production alongside specific examples of how Nuvec® can be used to improve delivery of nucleic acids.
The Company’s new PCT patent application claims priority from the Company’s United Kingdom patent application number 1718817.8. The PCT application will publish approximately 18 months from the priority date of 14 November 2017. Therefore publication is expected on or shortly after 14 May 2019. National phase entry is due 30 months from the priority date, in most countries. The national phasing deadline is therefore expected to be 14 May 2020.
Nigel Theobald, CEO of N4 Pharma commented:
“Having strong intellectual property for Nuvec® is important for commercial outlicensing and this new PCT patent application not only strengthens the intellectual property rights around Nuvec® but, if granted, would provide an extra 30 months protection for Nuvec® after expiry of the in licensed IP which, if granted, would likely expire in April 2036.
“As our work on Nuvec® progresses,we anticipate that subsequent patent applications will be filed to extend the protection for Nuvec® even further.”